Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome in Haploidentical Transplantation

Ramzi Abboud, Mark A. Schroeder, Michael P Rettig, Reyka G Jayasinghe, Feng Gao, Jeremy Eisele, Leah Gehrs, Julie K. Ritchey, Jaebok Choi, Camille N Abboud, Iskra Pusic, Meagan A Jacoby, Peter Westervelt, Matthew Christopher, Amanda F. Cashen, Armin Ghobadi, Keith Stockerl-Goldstein, Geoffrey L Uy, John F. DiPersio

Blood blood.2024026497.

https://doi.org/10.1182/blood.2024026497

Published: 2024

Includes: Supplemental data

Journal Articles

Safety and Efficacy of Axatilimab at 3 Different Doses in Patients with Chronic Graft-Versus-Host Disease (AGAVE-201)

Blood (2023) 142 (Supplement 1): 1.

https://doi.org/10.1182/blood-2023-186963

Published: 2023

Journal Articles

Duvelisib for Cytokine Release Syndrome Prophylaxis during CD19-Targeted CAR T Cell Therapy

Michael Slade, Michael P. Rettig, Zachary David Crees, Neha Mehta-Shah, Todd A Fehniger, Amanda F Cashen, Iskra Pusic, Geoffrey L Uy, Peter Westervelt, John DiPersio, Armin Ghobadi

Blood (2023) 142 (Supplement 1): 3470.

https://doi.org/10.1182/blood-2023-172439

Published: 2023

Journal Articles

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome with T-Cell Replete Peripheral Blood Haploidentical Transplantation

Ramzi Abboud, Mark A. Schroeder, Michael P. Rettig, Feng Gao, Julie K. Ritchey, Camille N. Abboud, Iskra Pusic, Peter Westervelt, Amanda F Cashen, Matt Christopher, Armin Ghobadi, Ramzi Abboud, Keith Stockerl-Goldstein, Geoffrey L Uy, John F. DiPersio, Leah Gehrs

Blood (2023) 142 (Supplement 1): 651.

https://doi.org/10.1182/blood-2023-180289

Published: 2023

Journal Articles

Phase I Study of Baricitinib Gvhd Prophylaxis in HLA-Matched, Peripheral Blood Allogeneic Hematopoietic Cell Transplant

Blood (2022) 140 (Supplement 1): 1875–1876.

https://doi.org/10.1182/blood-2022-157214

Published: 2022

Journal Articles

Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy

Blood (2022) 139 (8): 1177–1183.

https://doi.org/10.1182/blood.2021011532

Published: 2022

Includes: Supplemental data

Journal Articles

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study

Blood (2021) 138 (22): 2278–2289.

https://doi.org/10.1182/blood.2021012021

Published: 2021

Includes: Supplemental data

Journal Articles

Safety, Tolerability, and Efficacy of Axatilimab, a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment

Stephanie J. Lee, Mukta Arora, Zachariah Defilipp, Mohammad Issam Abu Zaid, Antonio Di Stasi, Vedran Radojcic, Michael L. Meyers, Hope Qamoos, Peter Ordentlich, Christine Quaranto, Aaron Schmitt, Yu Gu, Amandeep Salhotra, Iskra Pusic, Carrie Lynn Kitko

Blood (2021) 138 (Supplement 1): 263.

https://doi.org/10.1182/blood-2021-146050

Published: 2021

Journal Articles

Use of Belimumab for Prophylaxis of Chronic Graft-Versus-Host Disease

Iskra Pusic, Tanner Johanns, Stefanie Sarantopoulos, Haley Record, Kaitlynn Zeisset, Peter Westervelt, Amanda F. Cashen, Geoffrey L. Uy, Camille Abboud, Sr., John F. DiPersio

Blood (2021) 138 (Supplement 1): 3904.

https://doi.org/10.1182/blood-2021-146778

Published: 2021

Journal Articles

A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Ramzi Abboud, Feng Gao, Michael P. Rettig, Jeremy Eisele, Leah Gehrs, Nichols Wallace, Camille Abboud, Sr., Peter Westervelt, Geoffrey L. Uy, Amanda F. Cashen, Matt Christopher, Armin Ghobadi, Meagan A. Jacoby, Iskra Pusic, Keith E. Stockerl-Goldstein, John F. DiPersio, Mark A. Schroeder

Blood (2021) 138 (Supplement 1): 100.

https://doi.org/10.1182/blood-2021-144591

Published: 2021

Journal Articles

A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease

Blood (2021) 137 (7): 896–907.

https://doi.org/10.1182/blood.2020006892

Published: 2021

Includes: Supplemental data

Journal Articles

Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial

Blood (2020) 135 (2): 97–107.

https://doi.org/10.1182/blood.2019003125

Published: 2020

Includes: Supplemental data

Journal Articles

Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS

Eric Huselton, MD, Amanda F Cashen, MD, John F. DiPersio, MD PhD, Meagan Jacoby, MD, Iskra Pusic, MD, Rizwan Romee, MD PhD, Mark A. Schroeder, MD, Geoffrey L. Uy, MD, Peter Westervelt, MD PhD

Blood (2019) 134 (Supplement_1): 3915.

https://doi.org/10.1182/blood-2019-132065

Published: 2019

Journal Articles

Investigating the Effects of Clonal Hematopoiesis in Healthy Marrow and Blood Donors on the Outcomes of Recipients Following Hematopoietic Stem Cell Transplantation

Wing Hing Wong, BSc, Kevin Elliot, Iskra Pusic, MD, John F. DiPersio, MD PhD, Todd E Druley, MD PhD

Blood (2018) 132 (Supplement 1): 2180.

https://doi.org/10.1182/blood-2018-99-115427

Published: 2018

Journal Articles

Tocilizumab Is Safe after T-Cell Replete Peripheral Blood Haploidentical Donor Transplantation

Ramzi Abboud, MD BS, Michael Slade, MDMS, Kathryn Trinkaus, PhD, Camille N. Abboud, MD, John F DiPersio, MD PhD, Todd A. Fehniger, MDPhD, Geoffrey L. Uy, MD, Peter Westervelt, MDPhD, Ravi Vij, MDMBA, Mark A. Schroeder, MD, Iskra Pusic, MD, Armin Ghobadi, MD, Rizwan Romee, MD

Blood (2017) 130 (Supplement 1): 3213.

https://doi.org/10.1182/blood.V130.Suppl_1.3213.3213

Published: 2017

Journal Articles

Ibrutinib Inhibits cGVHD Pathogenic Pre-Germinal Center B-Cells and Follicular Helper Cells While Preserving Immune Memory and Th1 T-Cells

Blood (2017) 130 (Supplement 1): 4481.

https://doi.org/10.1182/blood.V130.Suppl_1.4481.4481

Published: 2017

Journal Articles

Amphiregulin Improves Stratification of the Refined Minnesota Acute Graft-Versus-Host Disease Risk Score: Results from BMT CTN 0302/0802

Blood (2017) 130 (Supplement 1): 72.

https://doi.org/10.1182/blood.V130.Suppl_1.72.72

Published: 2017

Journal Articles

Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML

Geoffrey L. Uy, MD, Michael P Rettig, PhD, Theresa Fletcher, Peter A Riedell, MD, Keith E. Stockerl-Goldstein, MD, Armin Ghobadi, MD, Meagan Jacoby, MD PhD, Amanda F. Cashen, MD, Rizwan Romee, MD, Iskra Pusic, MD, Camille N. Abboud, MD, Mark A. Schroeder, MD, Ravi Vij, MDMBA, Peter Westervelt, MDPhD, John F DiPersio, MD PhD

Blood (2017) 130 (Supplement 1): 816.

https://doi.org/10.1182/blood.V130.Suppl_1.816.816

Published: 2017

Journal Articles

A Pilot Study of CX-01 with Azacitidine for Treatment of Hypomethylating Agent-Refractory AML and MDS

Eric Huselton, MD, Amanda F. Cashen, MD, John F DiPersio, MD PhD, Meagan Jacoby, MD PhD, Iskra Pusic, MD, Rizwan Romee, MD, Geoffrey L. Uy, MD, Peter Westervelt, MDPhD

Blood (2017) 130 (Supplement 1): 5067.

https://doi.org/10.1182/blood.V130.Suppl_1.5067.5067

Published: 2017

Journal Articles

Ibrutinib for chronic graft-versus-host disease after failure of prior therapy

David Miklos, Corey S. Cutler, Mukta Arora, Edmund K. Waller, Madan Jagasia, Iskra Pusic, Mary E. Flowers, Aaron C. Logan, Ryotaro Nakamura, Bruce R. Blazar, Yunfeng Li, Stephen Chang, Indu Lal, Jason Dubovsky, Danelle F. James, Lori Styles, Samantha Jaglowski

Blood (2017) 130 (21): 2243–2250.

https://doi.org/10.1182/blood-2017-07-793786

Published: 2017

Includes: Supplemental data

NARROW

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome in Haploidentical Transplantation

Safety and Efficacy of Axatilimab at 3 Different Doses in Patients with Chronic Graft-Versus-Host Disease (AGAVE-201)

Duvelisib for Cytokine Release Syndrome Prophylaxis during CD19-Targeted CAR T Cell Therapy

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome with T-Cell Replete Peripheral Blood Haploidentical Transplantation

Phase I Study of Baricitinib Gvhd Prophylaxis in HLA-Matched, Peripheral Blood Allogeneic Hematopoietic Cell Transplant

Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study

Safety, Tolerability, and Efficacy of Axatilimab, a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment

Use of Belimumab for Prophylaxis of Chronic Graft-Versus-Host Disease

A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease

Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial

Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS

Investigating the Effects of Clonal Hematopoiesis in Healthy Marrow and Blood Donors on the Outcomes of Recipients Following Hematopoietic Stem Cell Transplantation

Tocilizumab Is Safe after T-Cell Replete Peripheral Blood Haploidentical Donor Transplantation

Ibrutinib Inhibits cGVHD Pathogenic Pre-Germinal Center B-Cells and Follicular Helper Cells While Preserving Immune Memory and Th1 T-Cells

Amphiregulin Improves Stratification of the Refined Minnesota Acute Graft-Versus-Host Disease Risk Score: Results from BMT CTN 0302/0802

Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML

A Pilot Study of CX-01 with Azacitidine for Treatment of Hypomethylating Agent-Refractory AML and MDS

Ibrutinib for chronic graft-versus-host disease after failure of prior therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only